Scynexis (SCYX) Interest & Investment Income (2016 - 2026)
Scynexis (SCYX) posted Interest & Investment Income of $535000.0 for Q1 2026, up 27.99% on a QoQ basis from $418000.0 in Q4 2025, and down 31.06% year-over-year from $776000.0 in Q1 2025.
Scynexis (SCYX) Interest & Investment Income (2016 - 2026) Analysis & Trends
Scynexis' Interest & Investment Income history runs 11 years deep, the most recent figure standing at $535000.0 for Q1 2026.
- Quarterly Interest & Investment Income fell 31.06% year-over-year to $535000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.9 million (down 49.49% YoY) and the FY2025 annual result came in at $2.2 million, down 49.27% from the prior year.
- Interest & Investment Income was $535000.0 for Q1 2026 at Scynexis, up from $418000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $1.4 million in Q4 2023 and bottomed at $13000.0 in Q1 2022.
- A 5-year average of $727000.0 and a median of $691000.0 in 2022 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 17175.0% — and 2025, when it tumbled 55.49%.
- Scynexis' Interest & Investment Income stood at $691000.0 in 2022, then surged by 97.4% to $1.4 million in 2023, then tumbled by 36.29% to $869000.0 in 2024, then plunged by 51.9% to $418000.0 in 2025, then rose by 27.99% to $535000.0 in 2026.
- Business Quant data shows SCYX's Interest & Investment Income at $535000.0 in Q1 2026, $418000.0 in Q4 2025, and $454000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 32.85 Mn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 41.80 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 28.10 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | - |
| 10 | Scynexis | 23.19 Mn | -13.57 Mn | - | 535,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 535,000.00 |
| Dec 31, 2025 | 418,000.00 |
| Sep 30, 2025 | 454,000.00 |
| Jun 30, 2025 | 510,000.00 |
| Mar 31, 2025 | 776,000.00 |
| Dec 31, 2024 | 869,000.00 |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.13 Mn |
| Mar 31, 2024 | 1.28 Mn |
| Dec 31, 2023 | 1.36 Mn |
| Sep 30, 2023 | 1.26 Mn |
| Jun 30, 2023 | 737,000.00 |
| Mar 31, 2023 | 587,000.00 |
| Dec 31, 2022 | 691,000.00 |
| Sep 30, 2022 | 531,000.00 |
| Jun 30, 2022 | 181,000.00 |
| Mar 31, 2022 | 13,000.00 |
| Dec 31, 2021 | 4,000.00 |
| Sep 30, 2021 | 8,000.00 |
| Jun 30, 2021 | 6,000.00 |